Abstract |
We treated 14 boys, six with gastric ulcers and eight with duodenal ulcers, to determine famotidine pharmacokinetics and its inhibition of gastric acid secretion (pharmacodynamics). Famotidine (1 mg/kg/day) was administered either intravenously or orally at a dose of 0.5 mg/kg twice a day (maximum: 40 mg/day). Blood samples were collected from all subjects and the intragastric pH monitored in eight. Pharmacokinetic parameters were calculated assuming a one-compartment model. Volume of distribution, elimination half-life, and area under the serum concentration-time curve were 1.52 +/- 0.37 l/kg, 2.29 +/- 0.38 h, and 1.14 +/- 0.32 ng.h/ml, respectively. The mean oral bioavailability of famotidine was 50.6%. Both intravenously and orally administered famotidine neutralized gastric acidity during sleep but failed to continuously maintain the intragastric pH > 5.0. All subjects' ulcers healed within 8 weeks. There were no side effects noted during famotidine treatment. Twice daily administration of 0.5 mg/kg famotidine for 8 weeks appears to be a tolerated and effective treatment of children with gastroduodenal ulcers.
|
Authors | A Nagita, M Manago, S Aoki, M Mino, K Suzuki, K Ashida |
Journal | Therapeutic drug monitoring
(Ther Drug Monit)
Vol. 16
Issue 5
Pg. 444-9
(Oct 1994)
ISSN: 0163-4356 [Print] United States |
PMID | 7846741
(Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Administration, Oral
- Adolescent
- Biological Availability
- Child
- Famotidine
(blood, pharmacokinetics, pharmacology)
- Gastric Acid
(metabolism)
- Gastric Mucosa
(drug effects, metabolism)
- Humans
- Hydrogen-Ion Concentration
- Injections, Intravenous
- Male
- Peptic Ulcer
(drug therapy, metabolism, physiopathology)
|